Cognitive Impairment Associated with Schizophrenia Market Size was ~USD 948.1 Million in 2023 and is Expected to Grow at a CAGR of 8.9% Through 2034, Estimates DelveInsight

DelveInsight's "Cognitive Impairment Associated With Schizophrenia (CIAS) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CIAS, historical and forecasted epidemiology as well as the CIAS market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Cognitive Impairment Associated with Schizophrenia Market with DelveInsight's In-Depth Report @ CIAS Treatment Market-
https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Cognitive Impairment Associated with Schizophrenia Market Report
• According to DelveInsight's analysis, the Cognitive Impairment Associated with Schizophrenia market in the 7MM was valued at approximately USD 948.1 million in 2023 and is projected to grow at a CAGR of 8.9% during the forecast period 2024-2034.
• The CIAS market size in the US was approximately USD 706.2 million in 2023, representing approximately 74% of the total 7MM market. The total CIAS market size of EU4 and the UK was approximately USD 180.5 million in 2023, while Japan's market was approximately USD 61.4 million.
• Boehringer Ingelheim's iclepertin (BI-425809), currently in Phase III clinical trials as part of the CONNEX-3 program, is anticipated to launch by 2026 for CIAS treatment and is estimated to generate approximately USD 933.4 million by 2034 in the 7MM - a figure that alone underscores the transformative potential of this asset.
• According to DelveInsight's estimates, in 2023, there were approximately 3 million diagnosed CIAS prevalent cases in the 7MM. The US accounted for 52% of total cases (~1.5 million), EU4 and the UK accounted for approximately 33%, and Japan represented 15% (~455,000 cases).
• In 2023, the US recorded approximately 2.7 million prevalent cases of schizophrenia, with approximately 1.3 million male and 667,000 female cases. EU4 and the UK had approximately 1.7 million diagnosed prevalent schizophrenia cases, with approximately 1.0 million male and 652,000 female cases.
• Currently, there are no FDA-approved therapies specifically for CIAS. Treatment typically involves off-label pharmacological approaches including second-generation antipsychotics and non-pharmacological methods such as cognitive remediation therapy and physical exercise programs, which offer limited and inconsistent cognitive benefits.
• Among EU4 countries and the UK, Germany led the CIAS market in 2023, generating approximately USD 49.4 million, followed by France and the UK both contributing around USD 83.7 million.
• The CIAS Companies include Boehringer Ingelheim, Recognify Life Sciences (Atai Life Sciences), Alto Neuroscience/MEDRx, Kynexis, Gabather AB, and others.
• Promising CIAS Therapies include Iclepertin/BI-425809 (Boehringer Ingelheim; Phase III), RL-007 (Recognify Life Sciences/Atai Life Sciences; Phase IIb), and ALTO-101 (Alto Neuroscience/MEDRx; Phase II), and others.

Stay ahead in the Cognitive Impairment Associated with Schizophrenia Therapeutics Market with DelveInsight's Strategic Report @ CIAS Market Outlook-
https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Cognitive Impairment Associated with Schizophrenia Epidemiology Segmentation in the 7MM
The epidemiology section provides historical, current, and forecasted CIAS prevalence scenarios across the 7MM - covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

• Total Prevalent Cases of Schizophrenia
• Total Diagnosed Prevalent Cases of Schizophrenia
• Total Diagnosed Prevalent Cases of CIAS
• Gender-Specific Diagnosed Prevalent Cases of Schizophrenia

Download the report to understand which factors are driving CIAS epidemiology trends @ CIAS Prevalence-
https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Cognitive Impairment Associated with Schizophrenia Emerging Drugs
• Iclepertin (BI-425809): Boehringer Ingelheim
Iclepertin is an investigational oral Glycine Transporter 1 (GlyT1) inhibitor aimed at treating CIAS. By modulating glycine levels in the synaptic cleft, it enhances NMDA receptor function, potentially improving synaptic plasticity and cognitive performance. The US FDA granted Breakthrough Therapy Designation to iclepertin in May 2021 for CIAS treatment. Iclepertin demonstrated significant cognitive benefits in a Phase II study with findings presented at the 33rd ECNP Congress in 2020, and is currently in Phase III evaluation as part of the CONNEX-3 program with an anticipated launch by 2026.

• RL-007: Recognify Life Sciences (Atai Life Sciences)
RL-007 is an innovative small molecule targeting CIAS that enhances synaptic plasticity by modulating excitatory neurotransmission and GABA-B receptor systems, improving cognitive functions including memory and executive skills. Positive Phase IIa results in 2021 underscored its pro-cognitive potential and safety profile. RL-007 is now in a Phase IIb proof-of-concept trial, with outcomes anticipated by mid-2025.

• ALTO-101: Alto Neuroscience / MEDRx
ALTO-101 is a brain-penetrant PDE4 inhibitor targeting cAMP - a molecule critical for cognition and neuroplasticity - delivered via a Transdermal Delivery System to minimize side effects while enhancing therapeutic efficacy. Phase I trials in April 2024 demonstrated improved pharmacokinetics and tolerability with the transdermal formulation, leading to a Phase II trial initiated in June 2024 with results expected in the second half of 2025.

Cognitive Impairment Associated with Schizophrenia Market Outlook
CIAS is a critical feature of schizophrenia, characterized by significant deficits across multiple cognitive domains including reasoning, problem-solving, social cognition, verbal and visual memory, working memory, attention, and processing speed. These impairments often precede the onset of overt psychosis, are linked to neurobiological changes in the prefrontal cortex, and tend to remain stable over the course of illness - playing a key role in determining long-term functional outcomes for patients.
Despite representing one of the most debilitating aspects of schizophrenia, no therapies are specifically approved for CIAS. Over 80% of schizophrenia patients experience significant cognitive impairment that remains without approved targeted treatment. Current management relies on second-generation antipsychotics - which offer modest, inconsistent cognitive benefits - alongside cognitive remediation therapy, physical exercise, and other non-pharmacological strategies.
The emerging pipeline - led by iclepertin, RL-007, and ALTO-101 - represents the first wave of targeted CIAS therapeutics advancing through clinical development. Iclepertin's anticipated 2026 launch is expected to be a watershed moment in the CIAS market, with projections of approximately USD 933.4 million in 7MM revenues by 2034.

"The Cognitive Impairment Associated with Schizophrenia market in the 7MM was valued at approximately USD 948.1 million in 2023 and is projected to grow at a CAGR of 8.9% through 2034, driven by the anticipated launch of iclepertin, RL-007, and ALTO-101 - the first targeted therapeutic candidates to advance meaningfully in addressing the significant unmet need in CIAS."

Get In-Depth Knowledge on CIAS Market Trends and Forecasts with DelveInsight @ CIAS Treatment Options-
https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Scope of the Cognitive Impairment Associated with Schizophrenia Market Report
• Coverage: 7MM
• Study Period: 2020-2034
• Forecast Period: 2024-2034
• CIAS Companies: Boehringer Ingelheim, Recognify Life Sciences (Atai Life Sciences), Alto Neuroscience/MEDRx, Kynexis, Gabather AB, and others
• CIAS Therapies: Iclepertin/BI-425809 (Boehringer Ingelheim; Phase III), RL-007 (Recognify Life Sciences; Phase IIb), ALTO-101 (Alto Neuroscience/MEDRx; Phase II), and others
• CIAS Therapeutic Assessment: Current off-label treatments and emerging targeted pipeline candidates
• Market Dynamics: Market drivers and barriers, SWOT and conjoint analysis, KOL views, and reimbursement landscape

Unlock Strategic Insights with DelveInsight's Comprehensive CIAS Market Report @ CIAS Market Drivers and Barriers-
https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Table of Content
1. Key Insights
2. Report Introduction
3. Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Cognitive Impairment Associated With Schizophrenia Background and Overview
7. Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Emerging Drugs
11. CIAS - 7MM Market Analysis
12. KOL Views
13. Unmet Needs
14. SWOT Analysis
15. Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cognitive-impairment-associated-with-schizophrenia-market

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.